The Chi-Mice® technological platform is dedicated to the development of relevant models for the selection of efficient anticancer therapies. Through the use of patient-derived xenografts to murine models reconstituted with a human immune system, we can assess your drugs under clinically-relevant conditions.
Pharmacological studies using low-passage human cancer tumor models remain essential to gain further insight into oncogenic mechanisms, and to test new adjuvant chemotherapy strategies. Generation of a large panel of human tumors from surgical specimens reproduces the diversity of cancer diseases for pre-clinical assays.
Oncodesign has implemented strict guidelines to ensure model’s reliability:
Because usual in vivo compound assessment does not take into account the contribution of human tumor microenvironment, Oncodesign has a process to develop rodent models bearing a human immune system in severely immunocompromised mice humanized with hPBMCs, human stem cells (HSC) or purified hNK cells.
Depending on your needs, we perform human immune system reconstitution, patient sample xenografting or both.
Our clients can acquire the models for in-house use or run preclinical studies at Oncodesign. Each model is associated to a large range of associated products such as TMAs, serum from tumor bearing animal, RNA extracts, stem cells and new cell lines to select the best model for your drug development needs, to identify biomarkers, new targets, and to develop stem cell applications.
Chi-Mice® Platform is built upon an international Biological Resource Network to collect patient or healthy biological samples, including rare pathologies, in compliance with ethical regulations.